These findings suggest that increased synovial SAE1/UBA2 levels may drive synovial glycolysis and joint inflammation in RA, positioning SAE1/UBA2 as potential therapeutic targets [66]. This evidence concerns the gene SAE1 and rheumatoid arthritis.